Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the dunnigan variety

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 3, 2012, Pages 785-792

  Simha, Vinaya ^a   Subramanyam, Lalitha ^a   Szczepaniak, Lidia ^b   Quittner, Claudia ^a   Adams Huet, Beverley ^b   Snell, Peter ^b   Garg, Abhimanyu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; LEPTIN; METRELEPTIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY FAT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FAMILIAL PARTIAL LIPODYSTROPHY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LEPTIN REPLACEMENT THERAPY; METABOLIC DISORDER; MODERATE HYPOLEPTINEMIA; OBSERVATIONAL STUDY; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; PARALLEL DESIGN; PRIORITY JOURNAL; SEVERE HYPOLEPTINEMIA; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; AGED; BLOOD GLUCOSE; BODY WEIGHT; ENERGY METABOLISM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INSULIN; LEPTIN; LIPIDS; LIPODYSTROPHY, FAMILIAL PARTIAL; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84858027751     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2229     Document Type: Article

References (26)

1. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A2002 Leptin-replacement therapy for lipodystrophy.NEngl JMed 346:570-578 (Pubitemid 34438818)
2. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A 2003 Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 26:30-35 (Pubitemid 36928991)
3. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, Cline GW, DePaoli AM, Taylor SI, Gorden P, Shulman GI 2002 Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 109:1345-1350 (Pubitemid 34546899)
4. Javor ED, Ghany MG, Cochran EK, Oral EA, DePaoli AM, Premkumar A, Kleiner DE, Gorden P 2005 Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy. Hepatology 41:753-760 (Pubitemid 40462937)
5. Ebihara K, Kusakabe T, Hirata M, Masuzaki H, Miyanaga F, Kobayashi N, Tanaka T, Chusho H, Miyazawa T, Hayashi T, Hosoda K, Ogawa Y, DePaoli AM, Fukushima M, Nakao K 2007 Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J Clin Endocrinol Metab 92:532-541
6. Beltrand J, Beregszaszi M, Chevenne D, Sebag G, De Kerdanet M, Huet F, Polak M, Tubiana-Rufi N, Lacombe D, De Paoli AM, Levy- Marchal C 2007 Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. Pediatrics 120:e291-e296
7. Haque WA, Shimomura I, Matsuzawa Y, Garg A 2002 Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 87:2395
8. Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P 2007 Longterm efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism 56:508-516 (Pubitemid 46427848)
9. Ruhl CE, Everhart JE 2001 Leptin concentrations in the United States: relations with demographic and anthropometric measures. Am J Clin Nutr 74:295-301 (Pubitemid 32802013)
10. Simha V, Garg A 2002 Body fat distribution and metabolic derangements in patients with familial partial lipodystrophy associated with mandibuloacral dysplasia. J Clin Endocrinol Metab 87:776-785 (Pubitemid 34158252)
11. Gorden P, Park JY 2006 The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction. Arch Physiol Biochem 112:114-118 (Pubitemid 44384779)
12. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS 2010 Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med 152:93-100
13. Chong AY, Lupsa BC, Cochran EK, Gorden P 2010 Efficacy of leptin therapy in the different forms of human lipodystrophy. Diabetologia 53:27-35
14. Garg A 2004 Acquired and inherited lipodystrophies.NEngl J Med 350:1220-1234 (Pubitemid 38339366)
15. Chan JL, Oral EA 2010 Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 16:310-323
16. Garg A, Peshock RM, Fleckenstein JL 1999 Adipose tissue distribution pattern in patients with familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 84:170-174 (Pubitemid 29036696)
17. Hegele RA, Kraw ME, Ban MR, Miskie BA, Huff MW, Cao H 2003 Elevated serum C-reactive protein and free fatty acids among nondiabetic carriers of missense mutations in the gene encoding lamin A/C (LMNA) with partial lipodystrophy. Arterioscler Thromb Vasc Biol 23:111-116 (Pubitemid 36091634)
18. Simha V, Garg A 2006 Lipodystrophy: lessons in lipid and energy metabolism. Curr Opin Lipidol 17:162-169
19. Garg A 2000 Gender differences in the prevalence of metabolic complications in familial partial lipodystrophy (Dunnigan variety). J Clin Endocrinol Metab 85:1776-1782 (Pubitemid 32269275)
20. Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clément K, Magré J, Gorden P 2008 Leptin therapy for partial lipodystrophy linked to a PPAR-γ mutation. Clin Endocrinol (Oxf) 68:547-554 (Pubitemid 351388716)
21. Farooqi IS, O'Rahilly S 2009 Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 89:980S-984S
22. Moran SA, Patten N, Young JR, Cochran E, Sebring N, Reynolds J, Premkumar A, Depaoli AM, Skarulis MC, Oral EA, Gorden P 2004 Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53:513-519 (Pubitemid 38419197)
23. McDuffie JR, Riggs PA, Calis KA, Freedman RJ, Oral EA, DePaoli AM, Yanovski JA 2004 Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 89:4258-4263 (Pubitemid 39244422)
24. Javor ED, Moran SA, Young JR, Cochran EK, DePaoli AM, Oral EA, Turman MA, Blackett PR, Savage DB, O'Rahilly S, Balow JE, Gorden P 2004 Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy. J Clin Endocrinol Metab 89:3199-3207 (Pubitemid 38951884)
25. Beltrand J, Lahlou N, Le Charpentier T, Sebag G, Leka S, Polak M, Tubiana-Rufi N, Lacombe D, de Kerdanet M, Huet F, Robert JJ, Chevenne D, Gressens P, Lévy-Marchal C 2010 Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin. Eur J Endocrinol 162:1083-1091
26. 16 March 2011 Amylin and Takeda voluntarily suspend clinical activities in obesity trial. Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited:, San Diego, CA, and Osaka, Japan. PRNewswire via COMTEX (press release)